CRISPR Therapeutics Valuation

Is 1CG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1CG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1CG's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1CG's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1CG?

Key metric: As 1CG is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 1CG. This is calculated by dividing 1CG's market cap by their current revenue.
What is 1CG's PS Ratio?
PS Ratio	21.2x
Sales	US$202.83m
Market Cap	US$4.09b

1CG key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	11.7x
Enterprise Value/EBITDA	-7.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 1CG's PS Ratio compare to its peers?

The above table shows the PS ratio for 1CG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	13.4x
MOLN Molecular Partners	31.3x	57.8%	CHF 188.0m
BSLN Basilea Pharmaceutica	3.4x	6.0%	CHF 510.3m
KURN Kuros Biosciences	16.8x	n/a	CHF 883.0m
IDIA Idorsia	2.1x	53.8%	CHF 158.0m
1CG CRISPR Therapeutics	21.2x	54.3%	CHF 4.1b

Price-To-Sales vs Peers: 1CG is expensive based on its Price-To-Sales Ratio (21.2x) compared to the peer average (13.4x).

Price to Sales Ratio vs Industry

How does 1CG's PS Ratio compare vs other companies in the European Biotechs Industry?

37 Companies	Price / Sales	Estimated Growth	Market Cap

37 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 1CG is expensive based on its Price-To-Sales Ratio (21.2x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is 1CG's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1CG PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	21.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 1CG's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Roche Holding

CHF 204.1b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

ROG

CHF 253.50

7.0%

Roche Holding

CHF 204.1b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

CHF 273.20

1.6%

9.4%

Bristol-Myers Squibb

US$100.3b

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

BMY

US$54.24